These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 6487126)
1. Antibody-dependent cellular cytotoxicity. Relation to stage and disease course in North American patients with nasopharyngeal carcinoma. Neel HB; Pearson GR; Taylor WF Arch Otolaryngol; 1984 Nov; 110(11):742-7. PubMed ID: 6487126 [TBL] [Abstract][Full Text] [Related]
2. Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study. Pearson GR; Neel HB; Weiland LH; Mulroney SE; Taylor W; Goepfert H; Huang A; Levine P; Lanier A; Pilch B Int J Cancer; 1984 Jun; 33(6):777-82. PubMed ID: 6329967 [TBL] [Abstract][Full Text] [Related]
3. A prospective evaluation of patients with nasopharyngeal carcinoma: an overview. Neel HB J Otolaryngol; 1986 Jun; 15(3):137-44. PubMed ID: 3014165 [TBL] [Abstract][Full Text] [Related]
4. Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. Neel HB; Pearson GR; Weiland LH; Taylor WF; Goepfert HH; Pilch BZ; Goodman M; Lanier AP; Huang AT; Hyams VJ; Levine PH; Henle G; Henle W Otolaryngol Head Neck Surg; 1983 Jun; 91(3):255-62. PubMed ID: 6308537 [TBL] [Abstract][Full Text] [Related]
5. IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Mathew GD; Qualtiere LF; Neel HB; Pearson GR Int J Cancer; 1981 Feb; 27(2):175-80. PubMed ID: 6169655 [TBL] [Abstract][Full Text] [Related]
7. Antibody-dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma. Pearson GR; Johansson B; Klein G Int J Cancer; 1978 Aug; 22(2):120-5. PubMed ID: 212366 [TBL] [Abstract][Full Text] [Related]
8. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Pearson GR; Weiland LH; Neel HB; Taylor W; Earle J; Mulroney SE; Goepfert H; Lanier A; Talvot ML; Pilch B; Goodman M; Huang A; Levine PH; Hyams V; Moran E; Henle G; Henle W Cancer; 1983 Jan; 51(2):260-8. PubMed ID: 6295597 [TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-related antibody. Changes in titers after therapy for nasopharyngeal carcinoma. Neel HB; Taylor WF Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1287-90. PubMed ID: 2173618 [TBL] [Abstract][Full Text] [Related]
10. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology. Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480 [TBL] [Abstract][Full Text] [Related]
11. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan. Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948 [TBL] [Abstract][Full Text] [Related]
12. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282 [TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets. Khyatti M; Stefanescu I; Blagdon M; Menezes J J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983 [TBL] [Abstract][Full Text] [Related]
14. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Neel HB; Pearson GR; Taylor WF Ann Otol Rhinol Laryngol; 1984; 93(5 Pt 1):477-82. PubMed ID: 6093669 [TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805 [TBL] [Abstract][Full Text] [Related]
16. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. Tanner JE; Wei MX; Alfieri C; Ahmad A; Taylor P; Ooka T; Menezes J J Infect Dis; 1997 Jan; 175(1):38-46. PubMed ID: 8985194 [TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. Pearson GR; Qualtiere LF; Klein G; Norin T; Bal IS Int J Cancer; 1979 Oct; 24(4):402-6. PubMed ID: 93578 [TBL] [Abstract][Full Text] [Related]
19. Nasopharyngeal carcinoma in American Children: Epstein-Barr virus-specific antibody titers and prognosis. Naegele RF; Champion J; Murphy S; Henle G; Henle W Int J Cancer; 1982 Feb; 29(2):209-12. PubMed ID: 6174465 [TBL] [Abstract][Full Text] [Related]
20. Increasing the accuracy and scalability of the Immunofluorescence Assay for Epstein Barr Virus by inferring continuous titers from a single sample dilution. Goh SM; Swaminathan M; Lai JU; Anwar A; Chan SH; Cheong I J Immunol Methods; 2017 Jan; 440():35-40. PubMed ID: 27983956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]